IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN BAUSCH + LOMB CORPORATION (BLCO), CONTACT THE LAW OFFICES OF HOWARD G. SMITH ABOUT POTENTIALLY PURSUING CLAIMS TO RECOVER YOUR LOSS.

NEW YORK, June 1, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Bausch + Lomb Corporation ("Bausch + Lomb" or the "Company") (NYSE: BLCO). Such ...

On March 27, 2025, Bausch + Lomb announced a voluntary recall of intraocular lenses on its enVista platform due to reports of toxic anterior segment syndrome, a potential complication in cataract ...

Purpose To report the largest cluster of Urrets–Zavalia Syndrome (UZS), which occurred as a sequel of toxic anterior segment syndrome (TASS) after uneventful cataract surgery, and to evaluate the ...

On March 27, 2025, BLCO disclosed that it had “[begun] to see an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with enVista® intraocular lenses (IOLs ...

On March 27, 2025, BLCO disclosed that it had “[begun] to see an increased number of reports of toxic anterior segment syndrome (TASS) in conjunction with enVista® intraocular lenses ...

The recall of intraocular lenses is currently being wrapped up by Bausch + Lomb, after reports of inflammatory reactions following cataract surgery.

By Adriano Marchese. Bausch + Lomb will return its enVista intraocular lenses to market following a voluntary recall in March after discovering they had certain production and material issues.

After a thorough investigation in collaboration with a globally recognized toxic anterior segment syndrome (TASS) expert and an advisory group of nearly 30 top cataract surgeons including American ...

The recall was initiated as a precautionary measure after cases of toxic anterior segment syndrome (TASS) were reported, which the company has since traced back to a raw material from an alternate ...